Genetic Engineering in CAR T Cells for Solid Tumors: Current State, Barriers and Future Developments
Human Gene Therapy · 2025-09 · 36 (17-18) · 1138-1153
DOI: 10.1177/10430342251372041 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Human Gene Therapy, online erschienen am 29.08.2025. Verfasst von Rodrigo A Redondo-Frutos und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hemato-Oncology Program, CIMA Universidad de Navarra, IdiSNA, Pamplona, Spain. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Adoptive, Receptors, Chimeric Antigen, Genetic Engineering. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 91 Literaturangaben.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T cell therapy has revolutionized treatment for hematological malignancies, yet translating this success to solid tumors remains challenging. Major obstacles include antigen heterogeneity, on-target off-tumor toxicity, limited infiltration and persistence, and the immunosuppressive tumor microenvironment (TME). The present review discusses recent engineering strategies designed to overcome these barriers. Innovations such as affinity-tuned and logic-gated CARs improve specificity and safety, while multi-antigen targeting helps address tumor heterogeneity by avoiding antigen escape. Gene-editing approaches enhance CAR T cell fitness by promoting memory phenotypes, metabolic resilience, and resistance to inhibitory signals imposed by the immunosuppressive TME. Additional modifications improve trafficking, enable extracellular matrix degradation, and reprogram CAR T cells to withstand the hostile conditions of the TME. Together, these advances reflect a growing shift toward rational CAR design and synthetic immunology, with the goal of achieving durable and safe responses in solid tumors. Early clinical trials show promise, and continued translational efforts will be key to unlocking the full therapeutic potential of CAR T cells in this setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hemato-Oncology Program, CIMA Universidad de Navarra, IdiSNA, Pamplona, Spain.
- Immunology and Immunotherapy Program, CIMA Universidad de Navarra, IdiSNA, Pamplona, Spain.
- Laboratory of Cellular Therapy, Division of Oncology, Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Modena, Italy.
- Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
- Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Spain.
- Hematology and Cell Therapy Department, Clinica Universidad de Navarra (CUN), IdiSNA. Pamplona, Spain.
ORCID-Profile: Paula Rodriguez-Marquez
Zitieren
APA
Redondo-Frutos, R. A., Justicia-Lirio, P., Barbero-Jimenez, C., Garnica, M., Trudu, L., Rodriguez-Marquez, P., Lasarte, J. J., Prosper, F., & Rodriguez-Madoz, J. R. (2025). Genetic Engineering in CAR T Cells for Solid Tumors: Current State, Barriers and Future Developments. Human Gene Therapy, 36(17-18), 1138-1153. https://doi.org/10.1177/10430342251372041
Vancouver
Redondo-Frutos RA, Justicia-Lirio P, Barbero-Jimenez C, Garnica M, Trudu L, Rodriguez-Marquez P, et al. Genetic Engineering in CAR T Cells for Solid Tumors: Current State, Barriers and Future Developments. Human Gene Therapy. 2025;36(17-18):1138-1153. doi:10.1177/10430342251372041
BibTeX
@article{RedondoFrutos2025,
author = {Redondo-Frutos, Rodrigo A and Justicia-Lirio, Pedro and Barbero-Jimenez, Carmen and Garnica, Maider and Trudu, Lucia and Rodriguez-Marquez, Paula and Lasarte, Juan J and Prosper, Felipe and Rodriguez-Madoz, Juan R},
title = {Genetic Engineering in CAR T Cells for Solid Tumors: Current State, Barriers and Future Developments},
journal = {Human Gene Therapy},
year = {2025},
volume = {36},
number = {17-18},
pages = {1138--1153},
doi = {10.1177/10430342251372041}
}
EUVIMED